Drugs / Lucatumumab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01275209 | Feb 2011 → May 2012 | follicular lymphoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00231166 | Sep 2005 → May 2009 | plasma cell myeloma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00108108 | Apr 2005 → Jun 2008 | B-cell chronic lymphocytic leukemia | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00670592 | Mar 2008 → Feb 2013 | Hodgkins lymphoma, non-Hodgkin lymphoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2008-11-10 | XOMA (US) LLC | XOMA Restructures Drug Development Collaboration Including Oncology Drug Candidate HCD122 xoma.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lucatumumab | “Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Rituximab-refractory Follicular Lymphoma” NCT01275209 ↗ |
| Known as | CHIR-12.12 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743038 ↗ |
| Known as | HCD122 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00108108 ↗ |
| Modality | Monoclonal antibody | “Anti-CD40 Monoclonal Antibody (HCD122)” NCT00108108 ↗ |
| Route | Intravenous | “Administered Intravenously” NCT00108108 ↗ |
| Target | CD40 | “Anti-CD40 Monoclonal Antibody (HCD122)” NCT00108108 ↗ |